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Abstract
Background
Male circumcision devices have the potential to accelerate adolescent voluntary medical
male circumcision roll-out. Here, we present findings on safety, acceptability and satisfac-
tion from active surveillance of PrePex implementation among 618 adolescent males (13–
17 years) circumcised in Zimbabwe.
Methods
The first 618 adolescents consecutively circumcised from October 2015 to October 2016
using PrePex during routine service delivery were actively followed up. Outcome measures
included PrePex uptake, attendance for post-circumcision visits and adverse events (AEs).
A survey was conducted amongst 500 consecutive active surveillance clients to assess
acceptability and satisfaction with PrePex.
Results
A total of 1,811 adolescent males were circumcised across the three PrePex active surveil-
lance sites. Of these, 870 (48%) opted for PrePex but only 618/870 (71%) were eligible.
Among the 618, two (0.3%) self-removals requiring surgery (severe AEs), were observed.
Four (0.6%) removals by providers (moderate AEs) did not require surgery. Another 6 (1%)
mild AEs were due to: bleeding (n = 2), swelling (n = 2), and infection (n = 2). All AEs
resolved without sequelae. Adherence to follow-up appointments was high (97.7% attended
7 day visit). A high proportion (71.6%) of survey respondents said they heard about PrePex
from a mobilizer; 49.8% said they chose PrePex because they wanted to avoid the pain
associated with the surgical procedure/surgery on their penis. Acceptability and satisfaction
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with PrePex was high; 95.4% indicated willingness to recommend PrePex to peers. A major-
ity (92%) reported experiencing pain when PrePex was being removed.
Conclusions
Active surveillance of the first 618 adolescent males circumcised using PrePex suggests
that the device is both safe and acceptable when used in routine service delivery among
13–17 year-olds. There is need to intensify specific demand generation activities for PrePex
male circumcision among this group of males.
Introduction
Over the last 10 years, at least 14 African countries have implemented voluntary medical male
circumcision (VMMC) for HIV prevention [1, 2]. By December 2017, a cumulative total of
18.6 million VMMCs (representing 90% of the global target of 20.8 million set in 2011) had
been performed in these countries [2]. The 18.6 million VMMCs had already averted an esti-
mated 230,000 new HIV infections by 2017 and this number is projected to grow to 1.1 million
by 2030 [2]. An important innovation in the delivery of VMMC has been the introduction of
medical devices for adolescent and adult male circumcision (MC) [3]. To date, two devices,
PrePex and ShangRing, have been prequalified by World Health Organization (WHO) and
can be used in VMMC programs supported by the President’s Emergency Plan for AIDS Relief
(PEPFAR) and the Global Fund for AIDS, Tuberculosis and Malaria [3, 4].
Medical devices for MC have the potential to accelerate VMMC roll-out by making the pro-
cedure easier, quicker and more widely accessible [5, 6]. Additionally, choice is an important
factor in enhancing acceptability and uptake of health services [3]. VMMC devices provide an
alternative for males who are hesitant to undergo conventional surgery. During active surveil-
lance of the PrePex device among adult males in Zimbabwe (conducted 2014), out of 2,156
men offered VMMC, 46.4% chose PrePex over conventional surgery [7], with some citing the
desire to avoid surgery on their penis as the main reason for choosing the device.
PrePex (a device which works by compressing the foreskin between a ring and an elastic
band, leading to distal tissue necrosis) [8] received WHO full prequalification in August 2016
after being assessed as set out in WHO Framework for Clinical Evaluation of Male Circumci-
sion Devices [9]. Following results from studies conducted in Rwanda [10, 11], additional
research with the device was conducted in Zimbabwe to establish its safety, efficacy and accept-
ability among providers and clients [12–14]. Data from these studies contributed to the pre-
qualification of PrePex by WHO for use in adults aged�18 years [15]. In addition to the
criteria defined in the Framework for Clinical Evaluation of Devices for Male Circumcision [9],
WHO also outlined an evaluation series that each country considering introduction of medical
devices for MC should complete.
The WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision recom-
mended active follow-up of the first 1,000 clients circumcised using a new device after prequal-
ification, and undertaken within the context of routine service delivery [16]. The main
purpose of the active follow-up (surveillance) is to assess safety through capturing, among
these 1,000 clients, all complications and adverse events under field (rather than research) con-
ditions. Zimbabwe was among the first countries to actively follow up 1,000 clients�18 years
circumcised using PrePex during routine service delivery [7].
Safety, acceptability of PrePex in adolescent active surveillance
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In late 2014, the WHO TAG on Innovations in Male Circumcision reviewed data on safety
and acceptability of PrePex in adolescents that were available from a bridging study involving
successful placements in 402 adolescents (13–17 years) in Zimbabwe [17]. The TAG also
reviewed partial findings from another PrePex study conducted in South Africa, which
included 89 males 13–17 years [18]. Based on findings from the two countries, the TAG rec-
ommended that PrePex use could be extended to include eligible adolescents 13–17 years, but
only under active surveillance since the numbers assessed were small but within the range
noted in the WHO clinical evaluation framework for a bridging study [19]. The TAG subse-
quently advised that active surveillance of adolescent PrePex VMMC be undertaken [19].
Following the TAG recommendation, Zimbabwe actively followed up adolescents 13–17
years circumcised using PrePex during routine service delivery, where the device was mar-
keted through various channels including mass media (radio, television); small media (news-
paper/brochure) and; interpersonal communication (VMMC mobilizer, health-care worker).
Of note, prior to undergoing MC, all males must be screened for medical eligibility, in particu-
lar the absence of any penile abnormalities and current genital infections [16]. With the PrePex
device, use may be further restricted due to additional anatomical reasons (e.g. phimosis—
inability to retract foreskin), a narrow foreskin opening or a short frenulum; or technical rea-
sons that preclude device placement (e.g. unavailability of a correct device size) [16].
Here, we present findings on acceptability, safety and satisfaction among all males 13–17
years circumcised using PrePex during active surveillance between October 2015 and October
2016.
Methods
Overview
Data presented here are from i) active surveillance of male adolescents consecutively circum-
cised using PrePex during routine service delivery between October 2015 and October 2016
and ii) a survey conducted amongst 500 consecutive active surveillance clients to assess accept-
ability and satisfaction with PrePex.
Active surveillance
Between 19 October 2015 and 31 October 2016, PrePex circumcisions were conducted at three
VMMC clinics in Zimbabwe’s two largest provinces (Harare n = 1 clinic, Bulawayo n = 2 clin-
ics). The three clinics had previously been sites for adult PrePex active surveillance [7].
VMMC staff at the three sites received refresher training on active surveillance standard oper-
ating procedures (SOP) and data collection tools. In addition, male researchers were deployed
at the three sites specifically for data collection and client follow up.
Outcome measures
Outcome measures for the active surveillance included i) percentage of male adolescents seek-
ing VMMC who opted for circumcision by PrePex rather than surgery, ii) percentage of Pre-
Pex clients failing to return to the clinic for scheduled follow up appointment on days 7, 14
and 49, iii) percentage of PrePex clients returning to the clinic for each scheduled appointment
after receiving reminders and iv) percentage of adverse events (AEs). AEs were classified
according to the surveillance SOP and PrePex AE guidelines. Of note, early removals (i.e.
within days 1–6 of placement) requiring surgery were classified as severe AEs, the rest were
recorded as moderate AEs. Pain was assessed using a visual analogue score with possible values
Safety, acceptability of PrePex in adolescent active surveillance
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of 0, 20, 40, 60, 80, and 100 where 0 corresponded to "no pain at all" and 100 to "most severe
pain" and measured at two time points—while wearing PrePex and at removal.
Client active follow-up
During active surveillance, all male adolescents (13–17 years) seeking VMMC at the three clin-
ics between October 2015 and October 2016 who opted and were eligible for circumcision
using PrePex, were actively followed up for their PrePex circumcision and post-op wound
care. Clients provided their mobile phone numbers and home addresses so they could be
tracked in the event that they missed a scheduled post-circumcision appointment. In addition,
clients were instructed to return to the clinic outside scheduled appointments if they experi-
enced any AEs or complications with the device.
For active surveillance, if a client failed to attend for their appointment seven days post cir-
cumcision (day 7), clinic staff made at least three attempts to contact him by phone and made
at least two home visits, if necessary. If a client failed to attend a scheduled appointment after
removal of the device (days 14 or 49), clinic staff made at least three attempts to contact him
by phone but no home visits were conducted. All missed appointments were rescheduled to a
time that was convenient to the client and consistent with clinic hours. If the client was unable
to attend, he was assessed over the phone using a standard set of questions to determine the
presence of AEs, the extent of wound healing and any wound care practices. AEs were docu-
mented at each appointment. All attempts to contact the client were recorded on a contact log
as were reasons reported for missing the scheduled appointment. Routine VMMC monitoring
data as per national guidelines were also collected.
Satisfaction survey
Five hundred consecutive active surveillance male adolescents who had undergone PrePex
male circumcision, attending for their scheduled appointment on day 14, were asked to take a
short interviewer-administered structured questionnaire. The questionnaire included ques-
tions from other PrePex acceptability and satisfaction studies [7, 20]. It was developed in
English and translated into Shona and Ndebele, Zimbabwe’s dominant indigenous languages,
also spoken and understood by smaller ethnic groups. It was then pretested with twenty 13–17
year-olds and subsequently refined based on their feedback. Questionnaire items explored
among others issues, reasons for choosing PrePex, satisfaction with the procedure as well as
perceptions of pain, odor and (in)convenience (S1 File).
Survey respondents were asked to indicate pain severity on a numerical scale ranging from
0 (no pain) to 100 (most severe pain). To enhance comparability of results, a pain score of at
least 60 was considered severe in line with a previous acceptability and satisfaction study
among adult men [7]. Survey respondents were also asked to indicate discomfort with odor on
a numerical scale ranging from 0 (no odor) to 100 (strongest odor). Additionally, they were
asked to indicate satisfaction with PrePex circumcision outcome on a numerical scale ranging
from 0 (no satisfaction) to 100 (highest satisfaction). The questionnaire was programmed
using Entryware software and tablets were used for data collection. Skip instructions and man-
datory data fields were used to ensure data validity, consistency and completeness. The ques-
tionnaire was administered by trained male researchers in either Shona or Ndebele.
Data processing and analysis
Active surveillance data from the three sites were entered into a database and analyzed to
ascertain the percentage of male adolescents seeking VMMC who chose PrePex over the surgi-
cal procedure, the percentage of PrePex clients failing to return to clinic (days 7, 14 and 49),
Safety, acceptability of PrePex in adolescent active surveillance
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the percentage of PrePex clients returning to the clinic for each scheduled appointment after
receiving reminders and, percentage of AEs.
Questionnaire data were downloaded into an Access database. Completeness and consis-
tency checks were performed. Any anomalies in the data were verified and corrected. Descrip-
tive analyses of key variables were performed. Data were analyzed using Stata 14. A chi-
squared test assessed association between pain at device removal and likelihood of recom-
mending PrePex to others; a p-value of<0.05 was considered significant.
Ethical considerations
This acceptability and satisfaction study (plus active surveillance/secondary data use) was
approved by the Medical Research Council of Zimbabwe (A/1810) and the University College
London ethics committee (2538/003). All acceptability and satisfaction study participants pro-
vided written informed assent in addition to caregiver consent.
Results
Active surveillance: PrePex preference, eligibility and uptake
Between 19 October 2015 and 31 October 2016, a total of 1,811 male adolescents (13–17 years)
were circumcised across the three PrePex active surveillance sites. Of these, 870 (48%) opted
for PrePex but only 618/870 (71%) were eligible. Reasons for PrePex ineligibility were adhe-
sions/tight foreskin (n = 134/252, 53.2%), mostly in 13 and 14 year-olds (n = 125/134, 93.3%);
presence of sexually transmitted infections (n = 5/252, 2%), all in 15–17 year-olds; urinary
tract infection (n = 2/252, 0.8) and biological penile anomalies (n = 12/252, 4.8%). In 99/252
adolescents (39.3%), the available PrePex device sizes were too large, mostly in 13 and 14 year
olds (n = 86/99, 86.9%); the remainder (n = 13/99, 13.1%) were 15–16 year olds.
Active surveillance: Frequency and outcomes of follow-up
There was good adherence to follow-up appointments with 604 (97.7%) clients returning to
the VMMC site for their scheduled appointment on day 7 without the need for any reminder.
All who did not return to the VMMC site for their day 7 appointment (n = 14, 2.3%) were suc-
cessfully tracked. Of these, 13 (92.9%) returned to the VMMC clinic on day 8 after at least 2
text message reminders and 2 call attempts. All cited school commitment as their reason for
missing the scheduled appointment. The remaining client (7.1%) returned on day 9 (Monday)
after missing a pickup vehicle deployed to help circumcised males attend for follow up on day
7 (Friday). A total of 112 (18.1%) adolescents circumcised using PrePex failed to attend their
scheduled appointment on day 14, and over two thirds 423 (68.4%) failed to attend for review
on day 49. All that missed the day 49 review but were later reached by phone (n = 417, 98.6%)
reported that complete healing had been achieved.
Safety: Adverse events
Table 1 summarizes AEs that occurred during active surveillance. A total of 12/618 (1.9%) AEs
were observed, of which six (1%) were classified as either moderate (n = 4) or severe (n = 2),
and six (1%) as mild, as per the active surveillance SOP. The two (0.3%) severe AEs were self-
removals and required surgery (severe AEs). In both cases, adolescents removed the device
themselves on day 2 due to pain and dorsal slit circumcision was perfomed 24 hours post self-
removal. The four (0.6%) moderate AEs were early removals by providers—because the clients
complained of pain (moderate AEs)—that did not require surgery. They occurred on days 5
(n = 3) and 6 (n = 1). In all cases, the foreskin had already necrotized and was easy to remove.
Safety, acceptability of PrePex in adolescent active surveillance
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Mild AEs were due to: bleeding (n = 2), swelling (n = 2), and infection (n = 2). All AEs resolved
without sequelae.
Survey: Source of information about PrePex
Between October 2015 and August 2016, 500 adolescents who had undergone PrePex male cir-
cumcision completed an interviewer-administered questionnaire when they attended the day
14 review appointment. None among all who attended during this period declined to take part
in the study. Table 2 summarizes sources of information about PrePex (also known as the
"ring"). Most of the respondents (71.6%) said they heard about PrePex from a VMMC mobili-
zer. The most-cited sources of information about PrePex were VMMC mobilizer (71.6%),
acquaintance (50.4%) and radio/television (29.6%).
Survey: Main reasons for choosing PrePex
Table 3 summarizes the main reasons for choosing PrePex. More than half of the respondents
(62.2%) said they chose PrePex because they wanted to avoid the pain associated with the sur-
gical procedure/surgery on their penis. Slightly over a quarter (26.8%) said it was so they could
continue with daily activities (including school and work). About 5% chose the device because
someone recommended/suggested it to them.
Survey: Acceptability and satisfaction with PrePex
Satisfaction with device was high with 487 (97.4%) respondents stating that they were satis-
fied/very satisfied with PrePex outcome. Device acceptability was also high with 477 adoles-
cents (95.4%) indicating that they were somewhat likely/very likely to recommend PrePex to
peers (Table 4). Dissatisfaction was due to penile swelling after removal and transient discolor-
ation of the inner foreskin.
Table 2. Sources of information about PrePex (N = 500).
Where respondent heard about "ring" Yes (%) No (%)
VMMC mobilizer 358 (71.6%) 142 (28.4%)
Friend/peer/parent/teacher 252 (50.4%) 248 (49.6%)
Radio/television 148 (29.6%) 352 (70.4%)
Health-care worker at VMMC site 78 (15.6%) 422 (84.4%)
Newspaper/brochure 76 (15.2%) 424 (84.8%)
Health-care worker (not at VMMC site) 15 (3%) 485 (97%)
Other 35 (7%) 465 (93%)
https://doi.org/10.1371/journal.pone.0213399.t002
Table 1. Number, nature and severity of PrePex VMMC AEs (N = 12).
No. (%) Nature Severity
6 (1%) Bleeding (n = 2
MildSwelling (n = 2)
Infection (n = 2)
4 (0.6%) Early removals by clinical staff (n = 3 day 5, n = 1 day 6) due to pain (no surgery required as
foreskin had already necrotized)
Moderate
2 (0.3%) Self-removals on day 2 (n = 2) due to pain (Both were classified as severe AEs because they
required surgery).
Severe
https://doi.org/10.1371/journal.pone.0213399.t001
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Survey: Perceptions of pain
A total of 425 (85%) respondents reported experiencing pain whilst wearing the device (days
2–7), with 108/425 (25.4%) estimating their pain severity to be 60–100%. More than half
(n = 249/425, 58.6%) reported experiencing pain on first two days of wearing the ring, 22.8%
days 3–4 and 18.6% days 5–7. Furthermore, 460 (92%) respondents reported experiencing
pain when the device was being removed, with 155/460 (33.7%) estimating their pain severity
to be 60–100%. Of the 460 respondents, 71 (15.4%) stated that they would have opted for surgi-
cal circumcision instead of PrePex if they had known the extent of pain. Sixty respondents
(13%) stated that they would have decided not to be circumcised at all (Table 5). Nearly two-
thirds (64.6%) said they did not wish anything.
Among 23 respondents who indicated that they were not at all likely/a little likely to recom-
mend PrePex to their peers, 8 (34.8%) ranked their pain during device removal to be at least
60% on the numerical scale. Among 477 respondents who indicated that they were somewhat
likely/very likely to recommend PrePex to peers, 147 (30.8%), (P = 0.85) ranked their pain sim-
ilarly at 60% or above.
Discussion
We present findings from active surveillance conducted among male adolescents circumcised
using the PrePex device between October 2015 and October 2016 (N = 618) during routine
service delivery in Zimbabwe. Two (0.3%) self-removals which required surgery (severe AEs),
were observed. Four (0.6%) early removals by providers due to pain (moderate AEs) did not
require surgery.
The low rate of severe or moderate AEs observed during active surveillance is consistent
with what was observed in adolescent PrePex research studies [17, 18] and surveillance of the
device among adult men [7]. Active surveillance among male adolescents suggests that PrePex
can be safely scaled up with this group in routine VMMC program roll-out. Nonetheless, the
Table 3. Main reasons for choosing PrePex ("ring")—N = 500.
Main reason N (%)
To avoid the pain associated with the surgical procedure/surgery on my penis 311 (62.2%)
So I could continue with my daily activities (including school and work) 134 (26.8%)
Someone who was circumcised with the ring recommended it to me 13 (2.6%)
My friends/peers/parents/teachers said I should try the ring 11 (2.2%)
Other 31 (6.2%)
https://doi.org/10.1371/journal.pone.0213399.t003
Table 4. Satisfaction with outcome and likelihood to recommend to peers (N = 500).
Satisfaction with outcome N (%)
Very satisfied 273 (54.6%)
Satisfied 214 (42.8%)
Dissatisfied 3 (0.6%)
Very dissatisfied 10 (2%)
Likelihood to recommend PrePex to peers
Very likely 370 (74%)
Somewhat likely 107 (21.4%)
A little likely 22 (4.4%)
Not at all likely 1 (0.2%)
https://doi.org/10.1371/journal.pone.0213399.t004
Safety, acceptability of PrePex in adolescent active surveillance
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relatively high ineligibility rate (mostly among 13 and 14 year-olds) highlighted the need for
smaller device sizes (which are now available - http://prepex.com/prepex-newsletters). Of
note, 2% were ineligible due to presence of sexually transmitted infections (STIs), highlighting
the importance of offering VMMC to adolescents as part of a comprehensive sexual and repro-
ductive health package [21–24].
All six (1%) moderate/severe AEs observed during active surveillance were pain-related.
The experience of pain was also reported in the survey where 425 (85%) respondents reported
experiencing pain whilst wearing the device and 460 (92%) when the device was being
removed. This was despite a change to the analgesic protocol for PrePex VMMC clients while
wearing the device (from Paracetamol to Ibuprofen) and at device removal (application of
local anesthetic cream) [7]. Other studies have also found that the PrePex procedure is charac-
terized by pain [7, 25–29]. VMMC programs therefore need to be honest and provide accurate
information about pain during pre-procedure counseling and conduct active pain manage-
ment as appropriate. This is particularly important since pain may result in self-removals,
likely leading to surgery. Concerning self-removals, client education needs to clearly articulate
that once placed, the device must remain in situ for seven days and if one desires to remove it,
he must return to the clinic where it may be removed with or without surgery [4]. Most impor-
tantly, the risks of removing the device at home should be emphasized. However, since some
early removals due to pain occur when the foreskin has already necrotized, VMMC programs
may need to offer clients the option of earlier device removal (i.e. on days 5 and 6).
Preference for PrePex during active surveillance (48%) was lower than anticipated and
lower than that of conventional surgery (52%). It had been assumed that extending the eligibil-
ity criteria to include adolescents aged 13–17 years would increase PrePex uptake [7, 30].
Given devices’ potential to accelerate VMMC roll-out by making the procedure easier, quicker
and more widely accessible [5, 6], our findings highlight the need to intensify specific demand
generation activities for PrePex male circumcision [6]. Demand creation will need to build on
the perceived comparative advantages of PrePex over conventional surgery and use these to
better sell the device.
Despite high levels of self-reported pain, acceptability and satisfaction with the device was
high among those clients who opted for it, with 95% of survey respondents indicating that they
would recommend the device to their peers, and 97% reporting satisfaction with procedure
outcome. These findings are consistent with what was observed in adolescent PrePex research
studies [17, 18]. Ensuring that AEs, including those related to pain are accurately communi-
cated and managed will likely maintain these high levels of satisfaction. Of note, a higher risk
of tetanus following circumcision with PrePex compared with other circumcision methods has
been noted, and WHO has shared further recommendations for device use and tetanus vacci-
nation status prior to device-enabled VMMC [31]. Moreover, post-operative wound infection
remains the most common post-procedure AE, particularly among adolescents [32–36], likely
due to poor post-VMMC client wound-management [31, 36–38]. The need for interventions
to enhance post-VMMC wound-care can never be overemphasized. Such interventions would
Table 5. What participants wished due to pain during device removal (N = 460).
As a result of the pain during ring removal, did you ever wish? N (%)
You had chosen to be circumcised surgically instead of using the ring 71 (15.4%)
You had not been circumcised at all 60 (13%)
I did not wish anything 297 (64.6%)
Other 27 (5.9%)
I did not experience pain 5 (1%)
https://doi.org/10.1371/journal.pone.0213399.t005
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give clear instructions on genital hygiene and wound-care, emphasize the benefits of prophy-
lactic tetanus vaccination, and underscore the dangers of applying traditional medicines and
substances to wounds [31, 38]. While the recommendation to restrict PrePex to individuals
sufficiently vaccinated against tetanus has tremendously reduced the number of PrePex-
enabled procedures [39], there might be opportunities for the device to be introduced in
school-based VMMC programs in combination with accompanying vaccination initiatives.
As with surveillance among adult men [7], there was high adherence (98%) to the scheduled
day 7 appointment. Similar follow-up rates to adults were observed on day 14 (82% vs. 80)
with lower follow up at day 49 (32% vs. 50%)–despite text message reminders and call
attempts. The sub-optimal attendance on day 49 is consistent with previous observations [40].
Among adolescents, this may also be explained by reliance on program pickup vehicles plus
the inability to meet the transportation costs involved (at least 1US$ each round trip). Indeed,
transportation costs have been reported as the largest out-of-pocket expenditure incurred by
VMMC clients [41]. Given the sub-optimal adherence to the day 49 follow-up appointment,
the absence of any AEs during this period, and subsequent assurances by clients reached by
phone that complete healing had been achieved, reviewing the post-circumcision follow-up
protocol will not only reduce the number of scheduled appointments but associated expenses
as well. Importantly, programs should continue to offer the minimum package of VMMC at
each visit including HIV testing, HIV prevention counseling, screening/treatment for STIs,
condom promotion, and the VMMC procedure [21–24].
Finally, participants indicated that they had mostly learned of PrePex from mobilizers and
acquaintances, suggesting the effectiveness of interpersonal communication in creating
demand for VMMC in general and PrePex-led VMMC, in particular. The success of these par-
ticipatory approaches in motivating males of all ages to take up VMMC has been reported in
other regional settings [42]. These approaches therefore need to be intensified if fast track tar-
gets [43] are to be achieved. Of note, only a few had learned of PrePex from health-care work-
ers, reflecting the well-recognized males’ general avoidance of the formal health system [44].
Indeed, VMMC is one of the few entry points through which health services can reach male
adolescents [45].
Limitations
A potential limitation of the findings presented here is that only the males who returned for
the day 14 visit were interviewed and therefore, they may not be representative of the entire
population that was circumcised using PrePex. Additionally, this active surveillance was lim-
ited to 618 adolescents. We had anticipated that surveillance would include 1,000 adolescents
and that this number of PrePex circumcisions would have been performed within <12
months. However, uptake was much slower than anticipated and we did not have resources to
continue active surveillance beyond 12 months. In addition, WHO had gathered sufficient evi-
dence to recommend that use of the PrePex device could be extended to eligible adolescents
13–17 years in August 2016 [4], making it unnecessary to continue in surveillance. This is,
however, one of the first initiatives to actively follow up male adolescents circumcised using
PrePex during routine service delivery. Findings will likely inform VMMC programs as they
scale up device-led adolescent VMMC in general and adolescent PrePex VMMC, specifically.
Conclusions
We successfully followed up the first 618 male adolescents circumcised using PrePex during
routine service delivery, and surveyed 500 of them to determine device safety as well as accept-
ability and satisfaction. Despite high levels of self-reported pain, we found that PrePex is both
Safety, acceptability of PrePex in adolescent active surveillance
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safe and acceptable when used in routine service delivery among male adolescents (13–17
years). Findings highlight the need to intensify specific demand generation activities for Pre-
Pex male circumcision among this group of males. Recently-introduced smaller device sizes
will partly address the high ineligibility observed so far. Lastly, these data suggest that it may
not be necessary to continue to advise males to return to the clinic 49 days after they have been
circumcised.
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